# Retinal Imaging in CNTF -Releasing Encapsulated Cell Implant Treated Patients for Early-stage Retinitis Pigmentosa

> **NCT01530659** · PHASE2 · COMPLETED · sponsor: **Neurotech Pharmaceuticals** · enrollment: 22 (actual)

## Conditions studied

- Retinitis Pigmentosa
- Usher Syndrome Type 2
- Usher Syndrome Type 3

## Interventions

- **DRUG:** NT-501
- **PROCEDURE:** Sham

## Key facts

- **NCT ID:** NCT01530659
- **Lead sponsor:** Neurotech Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-01
- **Primary completion:** 2019-07-01
- **Final completion:** 2019-07-01
- **Target enrollment:** 22 (ACTUAL)
- **Last updated:** 2023-02-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01530659

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01530659, "Retinal Imaging in CNTF -Releasing Encapsulated Cell Implant Treated Patients for Early-stage Retinitis Pigmentosa". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT01530659. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*